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Introduction
Candida spp. are a major cause of bloodstream infections
associated with high mortality. The epidemiology of Can-
dida infections is evolving, with a progressive shift from
Candida albicans to non-albicans Candida spp. charac-
terised by decreased susceptibility to azoles [1]. Most con-
cerning is Candida auris, a previously unrecognised Can-
dida species, which emerged as a novel cause of candi-
daemia and invasive candidiasis in 2009 [2, 3]. This new
fungal pathogen is a serious public health problem because
of its potential for nosocomial transmission and its ability
to develop resistance to all antifungal drug classes [2, 4].
Outbreaks of strains with different clonal origins have been
reported from all continents [2, 4]. C. auris has become the
fifth most common cause of candidaemia in India and mul-
tiple cases have been reported in Pakistan, South Korea, Is-
rael, Kuwait, South Africa, Kenya, United States, Colom-
bia and Venezuela [4, 5]. In Europe, major outbreaks have
occurred in London (UK) and Valencia (Spain) [6, 7].
However, C. auris has rarely been reported in other Euro-
pean countries, where it has been isolated only from trav-
ellers from endemic regions [4]. This epidemiological situ-
ation raises important concerns about strategies that should
be implemented to prevent the importation and spread of
C. auris in countries that are currently spared. We present
here an update of the situation in Switzerland and our rec-
ommended approach in terms of preventive strategies.
Candida auris in Switzerland
In Switzerland, the first case of C. auris was documented
in Geneva in October 2017. A 74-year-old female who
was on vacation in north-eastern Spain was admitted to
a local hospital with severe community-acquired pneumo-
nia requiring mechanical ventilation. C. auris was isolat-
ed from tracheal aspirates and the patient was treated with
meropenem and fluconazole. At day 18 of the hospital
stay, she was transferred to Geneva with acute respiratory
distress syndrome. Screening at various sites (tracheal as-
pirates, groin, auditory canal, urine) was positive for C.
auris, whereas multiple sets of blood cultures were neg-
ative for yeasts. After initial improvement and antibiotic
discontinuation, the patient developed septic shock of un-
known origin and ultimately died. C. auris was considered
as a coloniser and was probably not the cause of this
fatal outcome. C. auris was identified with MALDI-TOF,
with subsequent confirmation by sequencing of the internal
transcribed spacer (ITS) region. Antifungal susceptibility
testing with Sensititre YeastOne™ (Trek Diagnostics Sys-
tems) showed minimum inhibitory concentrations (MICs)
of 256, 4, 1, 0.06, 0.12, 0.06 µg/ml for fluconazole,
voriconazole, amphotericin B, caspofungin, anidulafungin
and micafungin, respectively. The patient was placed on
contact precautions, and her room was cleaned with a chlo-
rine-based solution and an active oxygen-based surface
disinfectant after discharge. Multiple environmental sam-
ples obtained from the room after cleaning were all nega-
tive for C. auris.
We retrospectively analysed the national cohort of candi-
daemia of the Fungal Infection Network of Switzerland
(FUNGINOS) comprising 2102 Candida bloodstream iso-
lates collected from 25 Swiss hospitals between 2004 and
2013. C. auris was not recovered during this period. All
isolates belonging to species closely related to C. auris,
which may have been potentially misidentified (four Can-
dida famata, two unspecified Candida spp. and five Sac-
charomyces cerevisiae), were retrospectively tested by
mass spectrometry (matrix-assisted laser desorption ioni-
sation-time of flight, MALDI-TOF) for confirmation.
Recommendations for microbiology laborato-
ries
Accurate and rapid identification of C. auris is crucial. C.
auris is misidentified by classical biochemical methods.
Vitek 2 YST (BioMérieux) and Phoenix (BD Diagnostics)
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cannot distinguish it from other Candida of the haemulonii
complex, C. famata, C. lusitaniae and C. sake. API-20C
AUX (BioMérieux) misidentified it as Rhodotorula gluti-
nis [8, 9]. It can be correctly identified by sequencing the
D1-D2 region of the 28S rDNA or by a qPCR targeting a
specific rDNA region of C. auris [10, 11].
Accurate and fast identification is also achieved with
MALDI-TOF, either the Biotyper (Bruker) or Vitek-MS
(BioMérieux) systems, but only the “research use only”
(RUO) libraries contain C. auris spectra (the FDA-ap-
proved IVD version does not) [8]. Some difficulties in ob-
taining a high score with direct deposit of C. auris on
the MALDI plate when using the Biotyper have been re-
ported [9]. Complete extraction following the manufactur-
er’s instructions is needed, and several deposits are recom-
mended to obtain better results. Additionally, the use of a
homemade database containing more spectra of C. auris
significantly improves the identification results [12].
Recommendations for infection control and
prevention
The potential of C. auris for inter-human transmission and
nosocomial outbreaks is unusual for a fungus, and may be
partly explained by its ability to form biofilms and survive
on dry or moist surfaces [4]. High rates of candidaemia,
persistent patient colonisation and persistence in the envi-
ronment despite adequate infection control measures were
the hallmarks of the C. auris outbreaks in the UK and
Spain [6, 7]. Therefore, effective infection control strate-
gies are crucial to prevent the emergence and spread of this
pathogen, especially in intensive care units. The decision
to establish a systematic C. auris screening policy should
be assessed by each hospital on the basis of the local epi-
demiology. A listing of preventive measures that can be
recommended in a country of very low prevalence, such
Switzerland, is presented in table 1. We currently suggest
targeted screening of patients with (1) documented C. au-
ris infection or colonisation in the past, (2) previous con-
tact with a known C. auris case, or (3) a recent stay in a
hospital where C. auris is endemic. Importantly, each in-
stitution should prepare to deal with an emerging C. auris
outbreak by establishing protocols for screening and dis-
infection procedures that can be applied as soon as a case
of C. auris infection or colonisation is detected. Screening
should involve swabbing axilla and groin, which have been
associated with the highest yield of detection [13], with the
optional addition of other sites (e.g., nose and/or clinically
relevant sites). Cultures can be performed directly on com-
mercial chromogenic Candida agar plates, where C. auris
produce colonies that usually appear white to rose or light
purple (depending on the culture medium) after 48 hours
of incubation at 37°C (fig. 1).
In countries with a high prevalence or in the setting of
nosocomial outbreaks, pre-culture at 40°C in selective
Sabouraud broths with a high-salt content and dulcitol or
mannitol as carbon source in accordance with the Centers
for Disease Control and Prevention protocol is recom-
mended [14].
Patients with C. auris should be isolated in a single-patient
room with contact precautions. Strict adherence to hand
hygiene is required. Equipment used for the infected/
colonised patient should not be shared with other patients.
Quaternary ammonium is not active against C. auris.
Therefore, for surface cleaning, chlorine-based or active
oxygen-based products with sporicidal activity (similar to
those used against Clostridium difficile) should be used
[15]. Decontamination of the room and medical equipment
with hydrogen peroxide vapour after discharge of the pa-
tient has been performed during outbreaks [7].
Recommendations for clinical management of
C. auris colonisation and infection
Treating C. auris colonisation with systemic antifungal
agents is not recommended. Persistent skin colonisation
is common and there are no well-established decoloni-
sation protocols. Daily chlorhexidine washes are recom-
mended, but their efficacy has not been demonstrated [7,
13]. For documented or suspected cases of C. auris infec-
tion, echinocandins represent the first-line treatment, with
>90% of strains remaining susceptible. Resistance to flu-
conazole is present in most cases, while voriconazole and
amphotericin B have variable activity [2, 10]. According
to antifungal susceptibility testing results, these later drugs
may be considered as second-line or salvage therapies.
Conclusions
The threat of C. auris is a serious consideration because
of the virulence of this pathogen, its multi-resistant profile
and its potential for nosocomial transmission and pro-
longed outbreaks, in particular among critically ill patients.
Microbiology laboratories should be aware of the diagnos-
Table 1: Recommendations for the prevention and management of Candida auris.
Question Subject Measures
Which patients should be screened for C. auris? Patients transferred from or with recent stay in
hospital with endemic C. auris
Patients with previous C. auris isolation
Direct contact (roommate) of C. auris case
Composite swab (axilla, groin ± nose ± specific clinical site)
Preemptive contact precautions and single room isolation (or patient co-
horting) until documented negative screening*
How to manage C. auris cases? Patients with C. auris isolated in clinical speci-
mens
Contact precautions and single room isolation (or patient cohorting) until
documented negative screening*
Decolonisation protocol with daily chlorhexidine washes
Avoid or remove catheters if possible or consider protective chlorhexi-
dine disks for catheter exit sites
Colonisation only: do not treat with systemic antifungals
Infection: treat with an echinocandin as first-line therapy. Reassess treat-
ment according to antifungal susceptibility testing results
Which measures of decontamination should be
applied for C. auris?
Direct environment of C. auris case (room,
shared equipment)
Use of chlorine-based or active oxygen-based products with sporicidal
activity (daily and at discharge)
Consider hydrogen peroxide vaporization at discharge
* Duration of isolation and contact precautions is not well defined. The Centers for Disease Control and Prevention recommends at least two negative screenings at least 1 week
apart in the absence of antifungal treatment.
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Figure 1: Typical white to pale pink aspect of two different C. auris isolates named isolate 1 (panel A) and isolate 2 (panel B) after 48 h of
growth on BBL CHROMagar Candida medium (Becton Dickinson Diagnostics Systems).Differentiation between C. auris (white to pale pink
colonies) and C. albicans (green to blue colonies) on BBL CHROMagar Candida (panel C) and chromID Candida (bioMérieux) (panel D).
tic challenges related to the identification of this pathogen.
Infection control protocols for screening and management
of C. auris infection/colonisation should be planned in
order to anticipate outbreaks, which can rapidly become
overwhelming and difficult to eradicate.
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